Brought to you by 
Dr. Reddy's Gains Cancer Rights from Eisai
07 Sep 2021
Executive Summary
Eisai Co. Ltd. granted Dr. Reddy's Laboratories Ltd. exclusive global rights (excluding Japan and Asia, and including an option in India) to develop and sell E7777, a fusion protein marketed and in development for various lymphomas.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dr. Reddy's Gains Cancer Rights from Eisai
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice